# Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

> **NCT06217757** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sichuan University** · enrollment: 45 (estimated)

## Conditions studied

- Lung Cancer
- Extensive-stage Small-cell Lung Cancer

## Interventions

- **RADIATION:** Low-dose radiotherapy
- **DRUG:** Etoposide
- **DRUG:** Cisplatin
- **DRUG:** Sugemalimab
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT06217757
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-18
- **Primary completion:** 2027-10-31
- **Final completion:** 2028-10-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06217757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06217757, "Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06217757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*